Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 29.07
- Piotroski Score 2.00
- Grade Buy
- Symbol (CRNX)
- Company Crinetics Pharmaceuticals, Inc.
- Price $57.01
- Changes Percentage (1.68%)
- Change $0.94
- Day Low $55.51
- Day High $58.04
- Year High $62.53
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $70.00
- High Stock Price Target $97.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.77
- Trailing P/E Ratio -11.86
- Forward P/E Ratio -11.86
- P/E Growth -11.86
- Net Income $-214,529,000
Income Statement
Quarterly
Annual
Latest News of CRNX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The NDC program offers advantages over ADCs by targeting GPCRs, allowing for selective internalization and intracellular cleavage....
By Yahoo! Finance | 1 week ago -
We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
Investors are attracted to unprofitable companies like Crinetics Pharmaceuticals despite risks. Analyzing its cash burn and runway, shareholders can assess its financial health and potential for growt...
By Yahoo! Finance | 3 months ago -
Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
Crinetics Pharmaceuticals focuses on rare endocrine diseases and tumors. Shares were sold at $43.86 each, totaling $131,580, amid a $3.53 billion market cap. Insider Stephen Betz sold 24,000 shares in...
By Yahoo! Finance | 5 months ago
